Brief: Ab2 Bio Signs Agreement With Nippon Shinyaku For Tadekinig Alfa

Nippon Shinyaku

27/01/2025 07:41

Jan 27 (Reuters) - AB2 BIO :
    * AB2 BIO SIGNS U.S. OPTION AND LICENSING AGREEMENT WITH
NIPPON
SHINYAKU FOR TADEKINIG ALFA FOR AN ULTRA-RARE AUTOIMMUNE DISEASE
    * AB2 BIO: NIPPON SHINYAKU HAS OPTION TO BUY EXCLUSIVE U.S.
RIGHTS
TO COMMERCIALIZE CO'S TADEKINIG ALFA
    * AB2 BIO: GETS EARLY PAYMENTS OF UP TO $36 MILLION,
ELIGIBLE FOR
MILESTONE PAYMENTS OF UP TO $650 MILLION

Source text:  ID:nGNXrFv8r 

 ((Reuters.Briefs@thomsonreuters.com;))